Abbott's recent acquisition of Guidant's vascular business was an important boost in the company's efforts to build a major cardiovascular franchise, but it was only the latest in a concerted effort to create a broad-based device business. One of the key architects of Abbott's growth in the field is COO Rick Gonzalez. In the an interview, Gonzalez looks back on a career that has taken him to the top at Abbott and reflects on what the Guidant deal and other important moves will mean to Abbott's device operations.
by David Cassak
Wouldn’t it be interesting if the ultimate winner in the sweepstakes for Guidant Corp. that has played out over...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.
The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.
Charles River's chief scientific officer Julie Frearson discusses how the agency's embrace of artificial intelligence is driving a fundamental shift in how companies must structure and manage their research data
A 25-year-old's “naive optimism” becomes the driving force behind one of biopharma's most ambitious AI ventures.
The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.
An interactive look at pharma, medtech and diagnostics deals made during August 2025. Data courtesy of Biomedtracker.
The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.
